{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'The IMP (TEV-50717 and placebo) must be', 'The IMP (TEV-50717 and placebo) must be', 'Drug', 'stored protected from light, at a controlled', 'stored protected from light, at a controlled', 'storage and', 'room temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to', 'room temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to', 'security', '77\u00b0F); however, storage between 15\u00b0C', '77\u00b0F); however, storage between 15\u00b0C and', 'specificatio', 'toand 30\u00b0C (59\u00b0F to is acceptable if', '30\u00b0C (59\u00b0F to 86\u00b0F) is acceptable if there is', 'n.', 'there is no alternative. The IMP should be', 'no alternative. The IMP should be stored in', 'stored in a dry, securely locked,', 'a dry, securely locked, substantially', 'substantially constructed cabinet or', 'constructed cabinet or enclosure with access', 'enclosure with access limited to authorized', 'limited to authorized staff.', 'staff.', 'Section 3.9.2 Drug Accountability', 'Empty, partially used, and unused IMP will', 'Empty, partially used, and unused IMP will', 'Drug', 'be returned to the sponsor or its', 'be disposed of, as agreed with the', 'disposal', 'designeedisposed of, as agreed with the', 'sponsor/development partner.', 'details.', 'sponsor/development partner.', 'Table 1: Study Procedures and Assessments', 'Informed consent/assent and/or co consent', 'Informed consent/assent', 'Provisions', 'for patients 14 years of age and older', 'on informed', 'consent/ass', 'ent have', 'been more', 'clearly', 'provided', 'Not applicable', 'W', 'Contact IRT and dispense IMP and', 'Addition of', 'patient diary.', 'footnote to', 'study', 'procedures', 'for', 'specificatio', 'n.', 'Table 1: Study Procedures and Assessments, footnote c (Other sections affected by this change:', '3.13.2 Procedures Before IMP Treatment [Baseline/Day 1])', 'Patients will be provided with a diary to', 'Patients will be provided with a diary to', 'Clarificatio', 'record meal times and critical information', 'record critical information on dosing.', 'n of diary', 'on dosing.', 'entries.', 'Section 3.13.1 Procedures for Screening and Enrollment', 'obtain a blood sample (53 mL) for', 'obtain a blood sample (3 mL) for', 'Blood', 'analysis of CYP2D6 genotype', 'analysis of CYP2D6 genotype', 'sample', 'quantity', 'specificatio', 'n.', '181']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Section 3.13.2 Procedures Before IMP Treatment (Baseline/Day 1) (Other sections affected by this', 'change: 3.13.3.1.2 Clinic Visits [Weeks 2, 4, and 6] and 3.13.3.2.1 Week 9)', 'dispense IMP (...) and patient diary', 'dispense IMP (...) and patient diary', 'Clarificatio', 'n that', 'patient', 'diaries', 'should also', 'be', 'dispensed at', 'these', 'visits/weeks', 'Section 4.4 Withdrawal Criteria and Procedures', 'The investigator also has the right to', 'The investigator also has the right to', 'Withdrawal', 'withdraw a patient from the study inif any', 'withdraw a patient from the study if any of', 'criteria', 'of the event of following events occur:', 'the following events occur:', 'elaboration.', 'a.', 'intercurrent illness,', 'a.', 'intercurrent illness', 'b. adverse events, (any patient', 'b.', 'adverse events (any patient who', 'who experiences an adverse', 'experiences an adverse event', 'event may be withdrawn from', 'may be withdrawn from the', 'the study or from study', 'study or from study treatment at', 'treatment at any time at the', 'any time at the discretion of the', 'discretion of the investigator as', 'investigator as indicated in', 'indicated in Section 7.1.7)', 'Section 7.1.7)', 'c. pregnancy (see Section 7.3), or', 'c. pregnancy (see Section 7.3)', ')', 'd. other reasons concerning the', 'd. other reasons concerning the', 'health or well-being of the', 'health or well-being of the', 'patient', 'patient, or in the event of', 'e.', 'lack of cooperation', 'e.', 'lack of cooperation- If a', 'f.', 'post-baseline QTcF value >500', 'f.', 'post-baseline QTcF value >500', 'msec or change from baseline', 'msec or change from baseline', '>60 msec (as described in', '>60 msec is found, the as', 'Sections 4.3 and 7.1.7). The', 'described in Sections 4.3 and', 'investigator should repeat the', '7.1.7). The investigator should', 'ECG assessment twice and', 'repeat the ECG assessment', 'compare the average of the 2', 'twice and compare the average', 'pre-treatment QTcF values', 'of the 2 pre-treatment QTcF', '(baseline and screening) to the', 'values (baseline and screening)', 'average of the 3 post-baseline', 'to the average of the 3 post-', 'QTcF values. The IMP must be', 'baseline QTcF values. The IMP', 'stopped for any confirmed post-', 'must be stopped for any', 'baseline QTcF value >500 msec', 'confirmed post-baseline QTcF', 'or increase from baseline >60', 'value >500 msec or increase', 'msec.', '182']\n\n###\n\n", "completion": "END"}